Maisra El-Bouseary

Dr. Maisra El-Bouseary

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
BHBrekhna Hassan
Brekhna Hassan
MIMuhammad Ijaz
Muhammad Ijaz
AKAsadullah Khan
Asadullah Khan
KSKirsty Sands
Kirsty Sands
GSGeorgios-Ion Serfas
Georgios-Ion Serfas
TWTimothy R. Walsh
Timothy R. Walsh

17 June 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
HAHayder M. Al-Kuraishy
Hayder M. Al-Kuraishy
AAAli I. Al-Gareeb
Ali I. Al-Gareeb
SASadiq M. Al-Hamash
Sadiq M. Al-Hamash
SCSimona Cavalu
Simona Cavalu
MEMaisra El-Bouseary
Maisra El-Bouseary
GBGaber El-Saber Batiha
Gaber El-Saber Batiha
Coronavirus disease 2019 (COVID-19) is caused by a novel virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2-induced hyperinflammation together with alteration of plasma proteins, erythrocyte deformability, and platelet activation, may affect blood viscosity. Thus, this review aimed to study the link between SARS-CoV-2 infection and alteration of blood viscosity in COVID-19 patients. In order to review findings related to hyperviscosity in COVID-19, we suggested a protocol for narrative review of related published COVID-19 articles. Hyperviscosity syndrome is developed in different hematological disorders including multiple myeloma, sickle cell anemia, Waldenstorm macroglobulinemia, polycythemia, and leukemia. In COVID-19, SARS-CoV-2 may affect erythrocyte morphology via binding of membrane cluster of differentiation 147 (CD147) receptors, and B and 3 proteins on the erythrocyte membrane. Variations in erythrocyte fragility and deformability with endothelial dysfunction and oxidative stress in SARS-CoV-2 infection may cause hyperviscosity syndrome in COVID-19. Of interest, hyperviscosity syndrome in COVID-19 may cause poor tissue perfusion, peripheral vascular resistance, and thrombosis. Most of the COVID-19 patients with a blood viscosity more than 3.5 cp may develop coagulation disorders. Of interest, hyperviscosity syndrome is more commonly developed in vaccine recipients who had formerly received the COVID-19 vaccine due to higher underlying immunoglobulin concentrations, and only infrequently in those who have not received the COVID-19 vaccine. Taken together, these observations are untimely too early to give a final connotation between COVID-19 vaccination and the risk for development of hyperviscosity syndrome, consequently prospective and retrospective studies are necessary in this regard.

8 August 2022 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
SAShadi Salem Alkhayyat
Shadi Salem Alkhayyat
HAHayder Al-kuraishy
Hayder Al-kuraishy
AAAli I. Al-Gareeb
Ali I. Al-Gareeb
MEMaisra El-Bouseary
Maisra El-Bouseary
AAAmal M. AboKamer
Amal M. AboKamer
Jesus Simal-GandaraJesus Simal-Gandara
Jesus Simal-Gandara

5 September 2023 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
AAAlanood Almurshedi
Alanood Almurshedi
TEThanaa A El-Masry
Thanaa A El-Masry
Hend SelimHend Selim
Hend Selim
Mostafa El-SheekhMostafa El-Sheekh
Mostafa El-Sheekh
MMMofida E. M. Makhlof
Mofida E. M. Makhlof
MEMaisra El-Bouseary
Maisra El-Bouseary
Background: Marine macroalgae have gained interest recently, mostly due to their bioactive components. Polycladia crinita is an example of marine macroalgae from the Phaeophyceae class, also known as brown algae. They are characterized by a variety of bioactive compounds with valuable medical applications. The prevalence of such naturally active marine resources has made macroalgae-mediated manufacturing of nanoparticles an appealing strategy. In the present study, we aimed to evaluate the antioxidant and anti-inflammatory features of an aqueous extract of Polycladia crinita and biosynthesized P. crinita selenium nanoparticles (PCSeNPs) via a carrageenan-induced rat paw edema model. The synthesized PCSeNPs were fully characterized by UV–visible spectroscopy, FTIR, XRD, and EDX analyses. Results: FTIR analysis of Polycladia crinita extract showed several sharp absorption peaks at 3435.2, 1423.5, and 876.4 cm−1 which represent O–H, C=O and C=C groups. Moreover, the most frequent functional groups identified in P. crinita aqueous extract that are responsible for producing SeNPs are the –NH2–, –C=O–, and –SH– groups. The EDX spectrum analysis revealed that the high percentages of Se and O, 1.09 ± 0.13 and 36.62 ± 0.60%, respectively, confirmed the formation of SeNPs. The percentages of inhibition of the edema in pretreated groups with doses of 25 and 50 mg/kg, i.p., of PCSeNPs were 62.78% and 77.24%, respectively. Furthermore, the pretreated groups with 25, 50 mg/kg of P. crinita extract displayed a substantial decrease in the MDA levels (P < 0.00, 26.9%, and 51.68% decrease, respectively), indicating potent antioxidant effect. Additionally, the pretreated groups with PCSeNPs significantly suppressed the MDA levels (P < 0.00, 54.77%, and 65.08% decreases, respectively). The results of immune-histochemical staining revealed moderate COX-2 and Il-1β expressions with scores 2 and 1 in rats pre-treated with 25 and 50 mg/kg of free extract, respectively. Additionally, the rats pre-treated with different doses of PCSeNPs demonstrated weak COX-2 and Il-1β expressions with score 1 (25 mg/kg) and negative expression with score 0 (50 mg/kg). Both antioxidant and anti-inflammatory effects were dose-dependent. Conclusions: These distinguishing features imply that this unique alga is a promising anti-inflammatory agent. Further studies are required to investigate its main active ingredients and possible side effects.

24 May 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
HAHayder Al-kuraishy
Hayder Al-kuraishy
AAAli I. Al-Gareeb
Ali I. Al-Gareeb
MEMaisra El-Bouseary
Maisra El-Bouseary
FSFatma I. Sonbol
Fatma I. Sonbol
Gaber El-Saber BatihaGaber El-Saber Batiha
Gaber El-Saber Batiha

17 October 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
HAHayder Al-kuraishy
Hayder Al-kuraishy
AAAli I. Al-Gareeb
Ali I. Al-Gareeb
NANisreen Khalid Aref Albezrah
Nisreen Khalid Aref Albezrah
HBHaitham Ahmed Bahaa
Haitham Ahmed Bahaa
MEMaisra El-Bouseary
Maisra El-Bouseary
Gaber El-Saber BatihaGaber El-Saber Batiha
Gaber El-Saber Batiha